SAN RAFAEL, Calif. (AP) _ BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported a fourth-quarter loss of $90.7 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the San Rafael, California-based company said it had a loss of 53 cents. Losses, adjusted for one-time gains and costs, came to 16 cents per share.
The results surpassed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.
The rare disease biopharmaceutical posted revenue of $300.1 million in the period, also surpassing Street forecasts. Ten analysts surveyed by Zacks expected $297.1 million.
For the year, the company reported that its loss widened to $630.2 million, or $3.81 per share. Revenue was reported as $1.12 billion.
BioMarin expects full-year revenue in the range of $1.25 billion to $1.3 billion.
BioMarin shares have increased nearly 8 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $89.29, a rise of 18 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BMRN at https://www.zacks.com/ap/BMRN
Keywords: BioMarin Pharmaceutical, Earnings Report